Evicenter
MarkdownMedical informationP&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Launch
Not announced
Last updated
93 sources

Formulary monograph

Tovecimig

Monograph section

FieldValue
DrugTovecimig (CTX-009 and ABL001)
Indication reviewedSecond-line advanced biliary tract cancer
Therapeutic categoryBispecific antibodies targeting DLL4 and VEGF-A
ManufacturerCompass Therapeutics
Regulatory statusNot approved in any country. FDA Fast Track designation granted April 2024 and orphan drug designation granted April 2026; FDA recommended in September 2026 a trial demonstrating a survival benefit before a biologics license application submission; the company continues to prepare one
Data as ofNovember 17, 2026
Review statusDraft for pharmacy and therapeutics committee review

Introduction

Disease background

Definition: biliary tract cancer and the anatomical subtypes of cholangiocarcinoma

Prevalence and the proportion of participants who reach second-line therapy

The second-line population: progression after first-line chemotherapy and immunotherapy

Natural history: late presentation, stage at diagnosis, and survival from diagnosis

Stage at diagnosisPercent of cases5-year relative survival
Localized“45%”“37.4%”
Regional“23%”“13.4%”
Distant“21%”“3.6%”
Unknown“10%”“11.6%”

Survival after progression on first-line therapy

Burden: quality of life, healthcare costs, and work loss

“One thousand and sixty-five patients with CCA were included (iCCA: n = 624 [58.6%]; eCCA: n = 380 [35.7%]). The mean age was 51.9-53.9 years across cohorts. In patients with iCCA and eCCA, respectively, the number of mean all-cause days absent PPPM for illness was 6.0 and 4.3, and 12.9 and 6.6% had ≥1 CCA-related short-term disability claim. Median indirect costs PPPM owing to absenteeism, short-term disability, and long-term disability, respectively, in patients with iCCA were $622, $635, and $690, and $304, $589, and $465 in patients with eCCA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In the absenteeism, short-term disability, and long-term disability cohorts, respectively, mean indirect costs associated with productivity loss contributed to 8.6, 7.2, and 6.7% of the total costs ($11,287, $11,887, and $11,977).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This suggests that patients in our analysis are more economically advantaged than the overall population of the United States, many of whom do not have access to paid sick leave or are not provided with insurance by their employers. Thus, our analysis may underestimate the productivity losses within the overall population of the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Development and regulatory status

Regulatory status: BLA in preparation after FDA feedback in September 2026

Pharmacology and usage

Mechanism of action

Pharmacodynamics

Clinical pharmacodynamic or target-engagement biomarkers

No evidence found.

Pharmacokinetics

Model parameter estimates

ParameterEstimate (relative standard error, %)
Clearance, L/h“0.0184 (18)”View highlighted excerpt for this quote
Central volume of distribution, L“3.87 (5)”View highlighted excerpt for this quote
Intercompartmental clearance, L/h“0.0207 (16)”View highlighted excerpt for this quote
Peripheral volume of distribution, L“1.31 (28)”View highlighted excerpt for this quote

Immunogenicity and pharmacokinetics in organ impairment

No evidence found.

Indications

Dosing and administration

Route and schedule recorded in the registry

Premedication, dose modification, and dosing in organ impairment

No evidence found.

Clinical efficacy summary

COMPANION-002

Design and population

Registered design details
Design featureRegistry record
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Single (Outcomes Assessor)”
Populations analyzed for efficacy and for safety
Analysis setTovecimig plus paclitaxelPaclitaxel
Intent-to-treat population, efficacy analyses“n=111”“n=57”
Population reported for treatment-emergent adverse events“n=108”“n=53”
Baseline demographics and disease characteristics, n (%) unless stated
CharacteristicTovecimig plus paclitaxel (n=111)Paclitaxel (n=57)
Median age, years“65.0”“63.0”
Male“53 (47.7)”“24 (42.1)”
Female“58 (52.3)”“33 (57.9)”
Asian“17 (15.3)”“10 (17.5)”
White“84 (75.7)”“40 (70.2)”
African American“4 (3.6)”“6 (10.5)”
Unknown or other race“6 (5.4)”“1 (1.8)”
Intrahepatic primary location“62 (55.9)”“30 (52.6)”
Other primary location (extrahepatic, gallbladder, ampullary)“49 (44.1)”“27 (47.4)”
ECOG performance status 0“53 (47.7)”“27 (47.4)”
ECOG performance status 1“58 (52.3)”“30 (52.6)”
Locally advanced disease“12 (10.8)”“5 (8.8)”
Metastatic disease“99 (89.2)”“52 (91.2)”

Endpoints

Registered secondary outcome measures
Outcome measureMeasure descriptionTime frame
“Progression Free Survival”“Time from randomization until the date of objective PD (as assessed by RECIST 1.1) or the date of death (by any cause in the absence of disease progression)”“From randomization to first documented objective PD or death if PD does not occur, average 6 months”
“Duration of Response”“The time between the date of the radiological evaluation that first confirmed CR or PR and the date of the radiation evaluation that first confirmed Progressive Disease (PD)”“From first confirmed CR or PR to confirmed PD, average 6 months”
“Overall Survival”“Time from randomization until the date of death by any cause. Patients who are still alive at the time of the analysis, or who have become lost to follow-up or withdrawn consent will be censored at their last date known to be alive”“From randomization to death from any cause, average 12 months”
“Disease Control Rate”“Percentage of patients whose BOR is assessed as CR, PR, or Stable Disease (SD)”“From randomization to treatment discontinuation for any reason, average 6 months”
“Incidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalities”“Incidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalities for all randomized patients who received at least one dose of study treatment (either CTX-009 or paclitaxel)”“From randomization to 60 days after the last dose of study treatment, average 7 months”

Efficacy results

Best overall response by blinded independent central review, intent-to-treat population
Best overall responseTovecimig plus paclitaxel (n=111)Paclitaxel (n=57)
Overall response rate (complete plus partial response)“19 (17.1%)”“3 (5.3%)”
Complete response“1 (0.9%)”“0 (0.0%)”
Partial response“18 (16.2%)”“3 (5.3%)”
Stable disease“49 (44.1%)”“19 (33.3%)”
Non-complete response / non-progressive disease“9 (8.1%)”“2 (3.5%)”
Progressive disease“18 (16.2%)”“24 (42.1%)”
Not evaluable“16 (14.4%)”“9 (15.8%)”
Efficacy summary with hazard ratios and two-sided p values
EndpointTovecimig plus paclitaxel (n=111)Paclitaxel (n=57)Hazard ratioTwo-sided p value
Overall response rate“19 (17.1%)”“3 (5.3%)”Not reported“p=0.031”
Progression-free survival, months“4.7”“2.6”“0.44”“p<0.0001”
Overall survival, intent-to-treat, months“8.9”“9.4”“1.05”“p=0.78”
Overall survival, crossover-adjusted by rank-preserving structural failure time, months“8.9”“9.4”“1.13”“p=0.65”

Limitations

ABL001-P1bC

Design and population

Endpoints

Efficacy results

Limitations

No evidence found.

2024-0279

Design and population

Study dates, status, and site
MilestoneRegistry record
Study start (actual)“2025-01-22”
Primary completion (estimated)“2027-05-01”
Enrollment (estimated)“50”
Recruitment status“Recruiting”
Last update posted“2026-09-09”

Endpoints

Efficacy results

No evidence found.

Limitations

No evidence found.

NOV150101-101

Design and population

Endpoints

Efficacy results

Limitations

No evidence found.

Clinical guidelines

Pan-Asian adapted ESMO Clinical Practice Guidelines (2024): first-line alternatives, second-line chemotherapy, molecularly directed therapy, locoregional therapy, and supportive care

“Oxaliplatin or carboplatin may be substituted for cisplatin when renal or auditory function is of concern, while gemcitabine plus S-1 can be an option for patients who present with or are susceptible to peripheral sensory neuropathy [II, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Gemcitabine monotherapy may be used in patients with a PS of 2 [IV, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“FOLFOX is the standard of care in the second-line setting after cisplatin-gemcitabine-based treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Irinotecan monotherapy or irinotecan- or liposomal irinotecan-based combination therapy may be considered [III, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Furthermore, FOLFOX treatment showed a limited survival benefit compared with active symptom control (6.2 months for FOLFOX versus 5.3 months for active symptom control).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Moreover, because the ABC-06 trial is the only positive phase III trial for the second-line treatment of BTC, the LoE was also downgraded from ‘I’ to ‘II’.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Ivosidenib is recommended for the treatment of patients with CCA and IDH1 mutations who have progressed after ≥1 prior line of systemic therapy [I, A; ESMO-MCBS v1.1 score: 2; ESCAT score: I-A; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“FGFR inhibitors are recommended for the treatment of patients with FGFR2 fusions who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“HER2-directed therapies can be considered in patients with HER2 overexpression/amplification who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Dabrafenib-trametinib is recommended for the treatment of patients with BRAFV600E mutations who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“NTRK inhibitors are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Selpercatinib can be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III; A; ESMO-MCBS v1.1 score for solid tumours with a RET fusion: 3; ESCAT score: I-C; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pembrolizumab is recommended in patients with MSI-H/dMMR who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pembrolizumab can be considered in patients with TMB-H tumours who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [IV; A; ESMO-MCBS v1.1 score for pembrolizumab in TMB-H solid tumours: 3; ESCAT Score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Local ablation could be considered as an option for patients with iCCA ≤3 cm who have contraindications or are otherwise unfit for surgery [III, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“SBRT can be considered for patients with iCCA in case of contraindication to surgery for liver-limited disease in the palliative setting [III, C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Intraarterial therapies, in combination with systemic ChT, can be an option for patients with liver-limited iCCA and discussed by the MDTB according to local availability [III, C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sepsis secondary to biliary obstruction is common and should be treated promptly [IV, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients should be advised of the likely duration of stent patency and of symptoms and signs which are indicative of biliary obstruction or infection [V, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

ESMO Clinical Practice Guideline interim update (2025): first-line chemoimmunotherapy and biomarker-directed later-line therapy

“Cisplatin–gemcitabine–durvalumab and cisplatin–gemcitabine–pembrolizumab are recommended as first-line therapy [I, A].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Cisplatin–gemcitabine combined with either pembrolizumab or durvalumab is a viable option for first-line treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At present, there are no discernible clinical, biochemical or molecular biomarkers, nor any notable differences in efficacy or toxicity, favouring one immune checkpoint inhibitor over the other.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Higher rates of treatment-related toxicity are observed with the addition of a third cytotoxic agent to gemcitabine–cisplatin in all of these regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Futibatinib [ESMO-Magnitude of Clinical Benefit (MCBS) v1.1 score: 3] and pemigatinib (ESMO-MCBS v1.1 score: 2) are recommended in patients with FGFR2 fusions or rearrangements who have progressed after one or more prior lines of systemic therapy [III, A; ESCAT score: I-B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These findings led to both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approval of pemigatinib and futibatinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Zanidatamab is recommended in patients with previously treated HER2-positive disease [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C; FDA approved, not EMA approved].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Trastuzumab deruxtecan should be considered in patients with HER2 overexpression and/or HER2 amplification who have progressed on or are intolerant to prior treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C; FDA approved, not EMA approved].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Zanidatamab is now FDA approved for previously treated, unresectable or metastatic HER2-positive BTC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“HER2 alterations, comprising amplifications and mutations, as well as human epidermal growth factor receptor 2 (HER2) protein overexpression, can be found in ∼5%-10% of BTC cases, with a higher prevalence observed in extrahepatic CCA and gallbladder carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most clinical trials focus on patients with HER2 overexpression and HER2 amplification, yet there are currently no standardised criteria for assessing HER2 status in BTC and no specific test can be recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Entrectinib (ESMO-MCBS v1.1 score: 3), larotrectinib (ESMO-MCBS v1.1 score: 3) and repotrectinib (not EMA or FDA approved) are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Selpercatinib should be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“NTRK fusions occur in <0.1% of BTC cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Because of the very low prevalence of these alterations, the respective inhibitors have only been evaluated in basket trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Safety summary

Contraindications

Cardiovascular, hemorrhagic, and gastrointestinal conditions excluded from COMPANION-002

Boxed warning

Warnings and precautions

Class-related events reported with other DLL4 and VEGF bispecific antibodies

“The treatment related adverse events (≥15% of patients) were hypertension (57.6%), headache (28.8%), fatigue (25.8%), and pulmonary hypertension (18.2%). Pulmonary hypertension was mostly asymptomatic at doses ≤5 mg/kg (6 Gr1, 1 Gr2), but was more severe at higher doses (4 Gr2, 1 Gr3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Twelve patients experienced pulmonary hypertension (6 asymptomatic Grade 1, 5 Grade 2 and 1 Grade 3) that was reversible upon drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Left-sided heart failure was the primary toxicity which limited the therapeutic index of the anti-DLL4 agents. Importantly, no cases of left-sided heart failure were observed in this study of dual DLL4/VEGF inhibition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“There were 19 (28.8%) patients that had navicixizumab withdrawn because of an adverse event. The most common adverse event that resulted in navicixizumab being withdrawn were: pulmonary hypertension (7 [10.6%] patients); hypertension (4 [6.1%] patients); and infusion-related reactions, fatigue, and increased BNP (2 [3.0%] patients each).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Single agent activity has been observed with anti-DLL4 therapy, but treatment duration was limited by cardiotoxicity that is believed to be due to the increased vascular sprouting which occurs when DLL4 is inhibited, but VEGF is not inhibited” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Common adverse reactions

COMPANION-002: treatment-emergent adverse events reported in at least 20% of participants, n (%), with the paclitaxel comparator arm

Adverse eventTovecimig plus paclitaxel (n=108), any gradeTovecimig plus paclitaxel (n=108), grade 3 or higherPaclitaxel (n=53), any gradePaclitaxel (n=53), grade 3 or higher
Hypertension“75 (69)”“56 (52)”“10 (19)”“3 (6)”
Fatigue“72 (67)”“16 (15)”“24 (45)”“3 (6)”
Neutropenia“59 (55)”“40 (37)”“20 (38)”“14 (26)”
Diarrhea“51 (47)”“6 (6)”“15 (28)”“1 (2)”
Anemia“48 (44)”“23 (21)”“17 (32)”“5 (9)”
Decreased appetite“44 (41)”“2 (2)”“11 (21)”“-”
Nausea“43 (40)”“2 (2)”“17 (32)”“-”
Proteinuria“37 (34)”“3 (3)”“5 (9)”“-”
Vomiting“36 (33)”“1 (1)”“13 (25)”“1 (2)”
Abdominal pain“35 (32)”“9 (8)”“13 (25)”“4 (8)”
Dyspnea“32 (30)”“5 (5)”“13 (25)”“-”
Epistaxis“32 (30)”“-”“4 (8)”“-”
Alopecia“32 (30)”“-”“28 (53)”“-”
Thrombocytopenia“33 (31)”“7 (7)”“6 (11)”“-”
Peripheral edema“35 (32)”“-”“7 (13)”“-”
Peripheral neuropathy“29 (27)”“2 (2)”“13 (25)”“1 (2)”
Constipation“30 (28)”“-”“8 (15)”“-”
Headache“25 (23)”“-”“7 (13)”“-”
Arthralgia“25 (23)”“-”“6 (11)”“-”

Drug interactions

Dedicated clinical drug interaction studies

No evidence found.

Special populations

Eligibility restrictions applied in COMPANION-002

Age, sex, and race of participants randomized in COMPANION-002

CharacteristicTovecimig plus paclitaxel (n=111)Paclitaxel (n=57)
Median age, years“65.0”“63.0”
Male, n (%)“53 (47.7)”“24 (42.1)”
Female, n (%)“58 (52.3)”“33 (57.9)”
Asian, n (%)“17 (15.3)”“10 (17.5)”
White, n (%)“84 (75.7)”“40 (70.2)”
African American, n (%)“4 (3.6)”“6 (10.5)”
Unknown or other, n (%)“6 (5.4)”“1 (1.8)”

Pediatric use, pregnancy and lactation, and dedicated renal or hepatic impairment pharmacokinetic studies

No evidence found.

Comparators and place in therapy

FOLFOX: guideline standing and reported outcomes in the second line

Liposomal irinotecan-based regimens: NIFTY, NALIRICC, and pooled individual patient data

Taxane-based chemotherapy in later-line practice and the rationale for the paclitaxel comparator

Share of patients eligible for a biomarker-directed option

FGFR2 fusion-directed inhibitors: prevalence, recommendations, and reported outcomes

HER2-directed therapy: alteration frequency, recommendations, and reported outcomes

“Confirmed objective responses by independent central review were observed in 33 patients in cohort 1 (41·3% [95% CI 30·4-52·8]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The median duration of response for the 33 patients in cohort 1 with a confirmed objective response was 12·9 months (95% CI 6·0–not estimable; range 1·5–16·9+) with 16 (49%) patients having ongoing responses at the time of the data cutoff (figure 2B; appendix p 5). No responses to zanidatamab were observed in cohort 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The median progression-free survival by independent central review in cohort 1 was 5·5 months (95% CI 3·7–7·2; range 0·3–18·5+; table 2; appendix p 6). Overall survival at 9 months was 69·9% (95% CI 57·8–79·1) for cohort 1; median overall survival data were immature at the time of data cutoff.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“16 patients (18%) had grade 3 treatment-related adverse events; of these, diarrhoea (four [5%] patients), ejection fraction decreased (three [3%]), and anaemia (two [2%]) occurred in more than one patient. No grade 4 or grade 5 treatment-related adverse events were reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Tumor-agnostic targeted and immune therapies: target frequency and recommendations

“Dabrafenib-trametinib is recommended for the treatment of patients with BRAFV600E mutations who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“NTRK inhibitors are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Selpercatinib can be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III; A; ESMO-MCBS v1.1 score for solid tumours with a RET fusion: 3; ESCAT score: I-C; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pembrolizumab is recommended in patients with MSI-H/dMMR who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pembrolizumab can be considered in patients with TMB-H tumours who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [IV; A; ESMO-MCBS v1.1 score for pembrolizumab in TMB-H solid tumours: 3; ESCAT Score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Care setting and administration schedule anticipated for tovecimig

Absence of a direct head-to-head comparison against an active second-line regimen

No evidence found.

Conclusion

References

  1. Abou-Alfa et al. (2020) (opens in a new tab)
  2. Azad et al. (2024) (opens in a new tab)
  3. Azad et al. (2026) (opens in a new tab)
  4. Banales et al. (2020) (opens in a new tab)
  5. Boilève et al. (2026) (opens in a new tab)
  6. Brindley et al. (2021) (opens in a new tab)
  7. CancerNetwork (2026) (opens in a new tab)
  8. Chen et al. (2024b) (opens in a new tab)
  9. ClinicalTrials.gov NCT03292783 (opens in a new tab)
  10. ClinicalTrials.gov NCT04492033 (opens in a new tab)
  11. ClinicalTrials.gov NCT05506943 (opens in a new tab)
  12. ClinicalTrials.gov NCT06548412 (opens in a new tab)
  13. Compass Therapeutics COMPANION-002 data presentation (2026) (opens in a new tab)
  14. Compass Therapeutics COMPANION-002 primary endpoint announcement (2025) (opens in a new tab)
  15. Compass Therapeutics COMPANION-002 survival data announcement (2026) (opens in a new tab)
  16. Compass Therapeutics corporate presentation (2026) (opens in a new tab)
  17. Compass Therapeutics Fast Track designation announcement (2024) (opens in a new tab)
  18. Compass Therapeutics first quarter results announcement (2026) (opens in a new tab)
  19. Compass Therapeutics Form 10-K (2026) (opens in a new tab)
  20. Compass Therapeutics Form 10-Q (2026) (opens in a new tab)
  21. Compass Therapeutics regulatory update announcement (2026) (opens in a new tab)
  22. Compass Therapeutics second quarter results announcement (2026) (opens in a new tab)
  23. Compass Therapeutics third quarter results announcement (2026) (opens in a new tab)
  24. Gordon et al. (2021) (opens in a new tab)
  25. Goyal et al. (2023) (opens in a new tab)
  26. Harding et al. (2023) (opens in a new tab)
  27. Javle et al. (2022) (opens in a new tab)
  28. Javle et al. (2026) (opens in a new tab)
  29. Jimeno et al. (2019) (opens in a new tab)
  30. Korea Biomedical Review (2026) (opens in a new tab)
  31. Lamarca et al. (2021) (opens in a new tab)
  32. Lamarca et al. (2026) (opens in a new tab)
  33. Lee et al. (2021) (opens in a new tab)
  34. Meric-Bernstam et al. (2024) (opens in a new tab)
  35. Na et al. (2024) (opens in a new tab)
  36. Nakamura et al. (2023) (opens in a new tab)
  37. Oh et al. (2023) (opens in a new tab)
  38. Parasuraman et al. (2023) (opens in a new tab)
  39. SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026) (opens in a new tab)
  40. Siegel et al. (2026) (opens in a new tab)
  41. Subbiah et al. (2020) (opens in a new tab)
  42. Vogel and Ducreux (2025) (opens in a new tab)
  43. Vogel et al. (2023) (opens in a new tab)
  44. Vogel et al. (2024a) (opens in a new tab)
  45. Vogel et al. (2024b) (opens in a new tab)
  46. Wang et al. (2024) (opens in a new tab)
  47. Yeom et al. (2020) (opens in a new tab)
  48. Yoo et al. (2021) (opens in a new tab)
  49. Yoo et al. (2025a) (opens in a new tab)
  50. Yoon and Yoo (2026) (opens in a new tab)
  51. Zhou et al. (2025) (opens in a new tab)
  52. Zhu et al. (2021) (opens in a new tab)